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Decades of studies provided a detailed view of the mechanism of
estrogen receptor-α (ERα) regulated gene transcription and the
physio-pathological relevance of the genetic programs controlled
by this receptor in a variety of tissues. However, still limited is our
knowledge on the regulation of ERα synthesis. Preliminary obser-
vations showed that the expression of ERα is cell cycle regulated.
Here, we have demonstrated that a well described polymorphic
sequence in the first intron of ERα (PvuII and XbaI) has a key role in
regulating the ERα content in cycling cells. We have shown that
the RNA Pol II (Pol II) elongation is blocked at the polymorphic site
and that the proto-oncogene c-MYB modulates the release of the
pausing polymerase. It is well known that the two SNPs are asso-
ciated to an increased risk, progression, survival and mortality of
endocrine-related cancers, here we have demonstrated that the
c-MYB-dependent release of Pol II at a specific phase of the cell cycle
is facilitated by the px haplotype, thus leading to a higher ERα
mitogenic signal. In breast cancer, this mechanism is disrupted
when the hormone refractory phenotype is established; therefore,
we propose this oscillator as a novel target for the development of
therapies aimed at sensitizing breast cancer resistant to hormonal
treatments. Because PvuII and XbaI were associated to a broad
range physio-pathological conditions beside neoplastic transfor-
mation, we expect that the ERα oscillator contributes to the reg-
ulation of the estrogen signal in several tissues.
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Estrogen receptor-α (ERα) is a member of the intracellularreceptor superfamily expressed in a wide variety of tissues
where it mediates a multiplicity of estrogen effects on re-
productive, skeletal, vascular and metabolic systems. ERα human
gene is dispersed over a region of more than 250 Kb in the long
arm of chromosome 6 where hundreds of single nucleotide
polymorphisms (SNPs) were identified. Among these, the re-
striction fragment length polymorphisms (RFLPs) PvuII (p/P or
IVS-397C/T or rs2234693, intron 1 nucleotide position 33,836)
and XbaI (x/X or IVS-351A/G or rs9340799, intron 1 nucleotide
position 33,882) were reported to be genetically linked to several
phenotypic traits and disorders influenced by estrogens. For
hormone-dependent cancers, association studies demonstrated
linkage of these polymorphisms to: (i) breast cancer risk (1),
survival (2), and mortality associated to hormone treatment (3);
(ii) insurgence of ductal type carcinoma (4); (iii) age of breast
cancer onset (5–7); (iv) predisposing factors (7), such as mam-
mographic density (8), age of menarche, and menopause (9); and
(v) endometrial (10) and prostate cancer risks (11). The func-
tional role of PvuII and XbaI SNPs in affecting these patholog-
ical phenotypes remains to be elucidated. The location of these
polymorphisms at the intron 1/exon 2 boundary suggests their
potential involvement in the regulation of ERα transcription.
Indeed, the sequence spanning the PvuII polymorphism was
demonstrated in vitro to bind the proto-oncogene c-MYB therein
proposed as a potential regulator of ERα expression (12). How-
ever, others molecular genetics studies could not conclusively
demonstrate an association between the PvuII site and receptor
contents in human breast cancers so far (1, 13) or even obtained
opposite results (14). However, ERα status is a valuable prognostic
and predictive biomarker in the management of breast cancer
patients (15). It is current belief that ERα mediates E2-induced
growth in endocrine cancers, thus, the receptor synthesis is a
plausible checkpoint in neoplastic transformation. The aim of the
present study was to assess the extent to which PvuII and XbaI
control ERα synthesis and how this is critical for neoplastic trans-
formation. Our work, by decrypting the functional role of PvuII and
XbaI polymorphic sites, provide an unexpected link among control
of Pol II elongation, oscillatory gene expression and hormonal
tumorigenesis.
Results
Blockage of Transcription Elongation at the First Intron of ERα. To
gain insight on PvuII/XbaI involvement in the regulation of ERα
transcription, we carried out a series of run on assays in MCF-7
breast cancer cells. We used as run on probes either the entire
ERα coding sequence or five DNA fragments mapping within the
receptor genomic locus in sense and antisense orientations. No
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antisense transcript was found. Sense transcripts were detected
in exon 1 and intron 1, but, not in exon 2, 4 and 8 (Fig. 1). Similar
results were obtained in T47D, another breast cancer cell line (SI
Appendix, Fig. S1). As control of hybridization capability of the
probes, run on experiments were also done on nuclei of SK-ER3
cells constitutively expressing a full length ERα cDNA: in this
case, all probes were equally able to detect the corresponding
transcripts (SI Appendix, Fig. S1C). These data suggested the
presence of an arrest of Pol II transcriptional elongation at in-
tron 1. To map the site responsible for the hypothesized Pol II
arrest, we used semiquantitative real-time PCR to measure the
relative concentrations of nuclear transcripts containing selected
intron 1 sequences in MCF-7 cells (Fig. 2 A and B). Consistent
with the run on data (Fig. 1), transcripts carrying the 5′ intron 1
region (start amplicon) were found to be significantly more
represented (33-fold) than those carrying the 3′ (end amplicon).
The levels of nuclear RNA containing the amplicon located
immediately upstream the SNPs (5′-SNP) were also significantly
higher (14-fold) than the transcripts containing the end amplicon,
pointing to a major block of transcription within the 532-bp se-
quence containing the two RFLPs (Fig. 2B). Similar enrichment of
the amplicons 5′ the SNPs were found in human normal and neo-
plastic endometrium (Fig. 2C). In accordance with these observa-
tions, Hah and collaborators reported accumulation of nuclear
transcripts at the intron 1-exon 2 boundary using a global run on
and sequencing approach (16). These results prompted us to ana-
lyze the nuclear transcripts from a larger biological sample size in-
cluding low-grade (n = 11) and high-grade (n = 11) human breast
cancers (SI Appendix, Table S1). To obtain an absolute measure of
the primary transcripts containing the 5′-SNP and end amplicons,
we carried out a quantitative PCR (qPCR) using the standard curve
procedure (SI Appendix, Fig. S2A) to measure the transcriptional
blockage in breast cancer cell lines (SI Appendix, Fig. S2B) and in
human breast samples (Fig. 2D and SI Appendix, Table S1). Pol II
pausing was clearly present in the cell lines and in about 80% of
the tumor samples. The magnitude of the pausing ratio appeared to
be significantly more pronounced in high grade than in low grade
tumors (Fig. 2D), although quite variable. To normalize the genetic
background variability, we measured the pausing ratio within the
same patient in the primary tumor and in the subsequent relapse.
Seven pairs of ERα-positive primary tumors/ERα-negative relapses
and two pairs of ERα-positive primary tumors/ERα-positive relap-
ses were analyzed (SI Appendix, Table S2): we observed a major,
statistically significant, increase (from 10 to more than 100 times)
of the Pol II blockage (Fig. 2E and SI Appendix, Table S2) during
relapse to ERα-negative tumors, whereas only a nonsignificant
trend to increase was observed in the ERα-positive recurrences,
suggesting that this mechanism may play a role in the development
of ER negative, hormone-refractory lesions.
Release of Pol II Blockage Is Regulated During Cell Cycle and
Correlates with ERα Oscillatory Expression. Oscillations of ERα
expression is known to occur during cell division (17–19). In
accordance to receptor fluctuation, our immunocytochemistry
studies in clones of MCF-7 showed a heterogeneous distribution
of the receptor, indicating that ERα expression could be cell
cycle-modulated (SI Appendix, Fig. S3A); interestingly, this het-
erogeneity is also often found in human endometrial and breast
cancer specimens and is used as a parameter for scoring tissues
for patient classification (15). We postulated that the mechanism
of Pol II block and release involving the intronic region could be
responsible of the ERα oscillatory expression during cell cycle.
By arresting the cell cycle at different phases, we initially showed
that the ERα content significantly decreased at the G1/S tran-
sition (SI Appendix, Fig. S3B). To investigate the kinetics of ERα
fluctuation, the experiment was repeated by measuring ERα
expression at different times after removal of the synchronizing
agent. Upon thymidine removal, 60–70% of the cells synchro-
nously reached the S-phase and returned in G1 20–24 h later as
Fig. 1. Block to transcription elongation at ERα intron 1. (A) The inserted
scheme represents the human ERα locus with the genomic position of the
run on probes (Upper). Autoradiography of the run on assay on MCF-7 cells
(Lower). Probe identity is indicated; s, single strand probes detecting sense
transcripts; a, single strand probes antisense transcripts. (B) Optical density
(OD) analysis of the autoradiographic signals; bars represent the signals
derived from sense transcripts normalized on the probe length vs. GAPDH
signal; white bars represent the signal generated by antisense transcripts.
Fig. 2. The Pol II block of transcription involves the PvuII and XbaI poly-
morphisms and is modulated during breast cancer progression. (A) Scheme
of the real-time PCR amplicons mapping within intron 1; P = PvuII and
x = Xba1 RFLPs. (B) Relative amount of the primary transcripts containing
the amplified sequences, bars are the average values ± mean SE (SEM) of the
fold enrichment versus the end amplicons. **P < 0.01 both start and the
5′-SNPs versus the end amplicon. (C) Same as (B) on RNA samples obtained
from normal and neoplastic human endometrium. **P < 0.01 both start or
5′-SNPs versus the end amplicon. (D) Pausing is calculated as the ratio be-
tween the absolute number of transcripts containing the 5′SNP and end
amplicons measured by quantitative real-time PCR from low and high grade
breast cancers. Bars are average values ± SEM *P < 0.05 calculated on the
pausing ratio of high versus low grade tumors with the Mann Whitney test.
(E) The pausing ratio defined as in (D) in primary breast cancers (white bars)
and relapses (dark gray or black bars) from n. 9 individuals; bars are averages
values ± SEM. #, in these cases, the end amplicon could not be detected, the
pausing ratio was higher than 50 times; **P < 0.01 pausing rate of relapse
versus primary breast tumors. All data were collected in at least two in-
dependent experiments performed in triplicate. Student t test was applied
to determine statistical significance.
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demonstrated by cytofluorimetry (Fig. 3). ERα mRNA was low
during the entire S phase and significantly increased in G2/M
and G1 after thymidine removal (Fig. 3A); consistent with this
observation, ERα protein was low in S-phase, increased in G1
and again decreased in the second S phase as demonstrated by
Western blot and immunocytochemistry studies (Fig. 3 B and C
and SI Appendix, Fig. S3C). Similar oscillatory mRNA and pro-
tein expression was observed in synchronized ZR 75.1 cells
(SI Appendix, Fig. S4). To correlate the Pol II block with the ERα
mRNA fluctuations during the cell cycle, we carried run on
assays with nuclei of MCF-7 cells at different cell cycle phases
(Fig. 4): In G1/S, transcription was barely detectable along the
whole locus; the transcription blockage observed in S phase was
released in late S/G2 phase (13 h after thymidine withdrawal)
and resumed 3 h later in G2/M phase. These data showed that
the production of a full-length ERα mRNA occurred only for
a short time window during the 3–6 h interval in late S/G2 phase.
These data suggested that the transient release of the Pol II
block from intron 1 initiates the oscillatory wave of ERα ex-
pression leading to a peak of receptor levels at G1.
An Evolutionary Conserved 76-bp Sequence Regulates Pol II Elongation
During Cell Cycle. Among the 532-bp sequence of intron 1 re-
sponsible of the Pol II elongation block (Fig. 2 A and B), a minimal
76-bp sequence (76inter1; i.e., 76 bp intervening sequence 1), con-
taining the two SNPs was found evolutionary conserved (SI Ap-
pendix, Fig. S5A) and therefore was tested for its ability to regulate
the Pol II release during cell cycle. To this aim, the 76inter1 sequence
was cloned downstream the SV40 promoter driving the luciferase
reporter gene (SI Appendix, Fig. S5B) and tested in transient trans-
fection experiments: the 76inter1 fragment significantly reduced
the reporter expression (SI Appendix, Fig. S5B). Next, we asked
whether the 76inter1 was responsible for the regulation of Pol II
elongation occurring during cell cycle (Fig. 4), and what was the
role of different PvuII/XbaI haplotypes in this process. The effects
of each of the four haplotypes (Fig. 5A) were tested in thymidine
synchronized MCF-7 cells transfected with the four constructs. We
found that Luciferase transcription was low in S-phase for all
constructs, but increased up to sevenfold (for the px containing
construct) in late S/G2 phase to decrease at baseline levels at
the beginning of G1 phase (Fig. 5B). The highest transcriptional
activity was observed for the px containing construct suggesting that
this haplotype is coupled with a higher rate of Pol II elongation in
late S/G2 phase. These data also indicated that the effect of the
haplotype on transcription could be appreciated only in the late
S/G2 phase, whereas, in S phase, transcription is prevented for all
haplotypes. In agreement with this conclusion, Pol II was found
blocked at the polymorphic site even in cells carrying an homozy-
gous px/px genotype, like the T47D (SI Appendix, Figs. S1 and S2).
The PvuII and XbaI Haplotype Configuration Influences the Amplitude
of ERα Fluctuation During Cell Cycle. To demonstrate that px
facilitates Pol II read-through also in the chromosomal context,
we set up an allele-specific real-time PCR protocol that was
applied to the nuclear RNA transcripts obtained from synchro-
nized MCF-7 cells (which carries px and PX haplotypes) in
S, late S/G2 and G1 phase. This assay is based on the ability of
oligonucleotide probes to discriminate the nuclear transcripts
generated by heterozygous alleles at the XbaI polymorphic site.
The analysis demonstrated a significantly higher amount of trans-
cripts carrying the px haplotype (compared with those carrying the
PX) in all phases of the cell cycle (Fig. 5C) with a px/PX ratio of
transcription of 6.7 fold in S phase, which significantly increased up
to 14.3 fold in late S/G2, to decrease at 7.1 fold in G1. We con-
cluded that also in the chromosomal context the px haplotype
allowed a more efficient Pol II elongation when the blockade is
released in late S/G2. Consistent with this observation, we found
a prevalence of the px transcripts in low/high-grade breast cancers
(SI Appendix, Table S1) and in endometrium (SI Appendix, Table
S3) human samples; the transcription ratio (px/PX or Px/PX)
varied, in some cases was as much as 3,000 times higher and in one
case the px was the only allele transcribed (Fig. 5D). To gain more
insights into the mechanism, we have investigated the recruitment
of Pol II, upstream, within and downstream the SNPs site in the
context of the px or PX alleles by chromatin immunoprecipitation
(ChIP) and allele specific amplification assays. ChIPs were carried
out with Pol II specific antibodies including anti-total Pol II and
anti-phosphorylated isoforms of Ser5 and Ser2 of the CTD. The
results showed that activated Pol II (Ser2 and Ser5 phosphory-
lated) was significantly accumulated upstream the SNP sites (Fig.
5E) and mostly on the px allele (Fig. 5F). Activated Pol II is thus
enriched at the site of pausing and is ready to be released upon
appropriate stimulations occurring during late S/G2 phase of the
cell cycle.
The Proto-Oncogene c-MYB Differentially Regulates the Release of
the Pol II Block at the Polymorphic Site. Based on the hypothesis
of the existence of a cell factor able to recognize the ERα intron
1 and facilitate Pol II elongation, we carried out a large series of
transfection experiments using the assay reported in SI Appendix,
Fig. S5B to test the effect of several proteins and signaling
pathways (SI Appendix, Table S4); although some factors dis-
played a significant activity in strengthening the block of Pol II
Fig. 3. Intracellular ERα concentration fluctuates during the cell cycle. After
thymidine washout cells were harvested at different cell cycle phases. ERα
mRNA and protein content were measured by Northern blot (A), Western
blot (B), and immunocytochemistry analysis (C). Bars in the graphs represent
ERα mRNA levels normalized with 28S ribosomal RNA (A) and ERα protein
content normalized with tubulin (B). Similar data were obtained at least in
two independent experiments. (C) Immunocytochemistry was carried out as
in (A) on cells at the indicated phases of the cell cycle: asynchronous cells
(As), first S (I), G1, and second S (II). Cell cycle phases were determined by
cytofluorometry.
Fig. 4. Pol II block is released in the late S/G2 phase of the cell cycle. (A)
Representative autoradiography of filters hybridized with 32P-labeled pri-
mary transcripts obtained from nuclei of MCF-7 cells taken after release from
the thymidine block at the indicated time points; the experiment was re-
peated twice. (B) OD analysis of the autoradiographic signals; bars represent
the signals derived from hybridization normalized on the probe length vs.
GAPDH signal.
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elongation (NFYA, Phorbol ester, LeptomycinB, LiCl), these
experiments enabled us to identify c-MYB as a good candidates
for the release of Pol II elongation. Interestingly, c-MYB had
been previously proposed as a modulator of ERα gene tran-
scription through the PvuII RFLP sequence (12), although the
mechanism underlying this activity had never been investigated.
To verify whether c-MYB was able to bind the chromatin sur-
rounding the ERα intron 1 polymorphic site, we overexpressed
a HA-tagged c-MYB (20) in MCF-7 cells (SI Appendix, Fig. S6A)
and immunoprecipitated the chromatin bound c-MYB using
anti-HA, anti-c-MYB and anti IgG antibodies (Fig. 6A). We
found a specific c-MYB enrichment in the chromosomal region
surrounding the two polymorphisms and in the CCNB2 promoter
used as a positive control; no amplification signals were visible
when unspecific IgG or primers mapping at – 35 Kb upstream
were used (Fig. 6A and SI Appendix, Fig. S6B). Indeed, a cluster
of potential c-MYB binding sites is present in the region sur-
rounding the SNPs (the frequency of the site in the remaining
sequence of the intron is about one in 1.5 Kb) including the
PvuII polymorphic site proposed (12) as a putative MYB regu-
latory element (SI Appendix, Fig. S6D). Modulation of c-MYB
expression directly influenced Pol II elongation, since increased
or decreased c-MYB expression reduced (Fig. 6B) or increased
the pausing ratio (SI Appendix, Fig. S6 E and F). c-MYB activity
was shown highest on the px allele in the transfection assay (SI
Appendix, Fig. S6C), therefore we analyzed the effects of the
transcription factor overexpression in the chromosomal context of
the endogenous gene; to this aim, we measured the enrichment of
the px allele and the ratio of the nuclear transcripts carrying the px
and PX allele in ChIP experiments carried out using anti-HA
antibody in c-MYB overexpressing cells (Fig. 6 C and D). A sig-
nificant increase of the px allele in the immunoprecipitate and an
increased level of px transcripts were observed in c-MYB over-
expressing cells, confirming that c-MYB preferentially binds and
differentially facilitates the release of Pol II elongation depending
on the PvuII/XbaI haplotype in the endogenous ERα gene leading
to the increased production of mature ERα mRNA (Fig. 6E).
Interestingly, previous works described an analogous mechanism
of regulation by ERα on the Pol II release on the c-MYB gene
(21), suggesting that a reciprocal regulation between these two
transcription factors is occurring at the level of Pol II elongation.
In keeping with this reciprocal regulation, c-MYB expression is
low during the S-phase both in MCF-7 and ZR 75.1 cell lines (SI
Appendix, Fig. S7). This low expression is not just a consequence
of the reported ERα regulation of c-MYB (21), because the
Fig. 5. Higher rate of Pol II elongation is associated with the px haplotype.
(A) Scheme of the 76inter1 DNA fragments subcloned into the pGL3 vector
carrying the four different haplotypes (px, Px, pX, PX). These constructs were
transfected in MCF-7 cells. (B) Bars are the ratio of the relative light units
(RLU) (normalized on β-galactosidase activity) of each haplotype containing
construct versus the empty vector measured in transfected cells in S, late
S/G2, and G1 phases; *P < 0.05, px vs. Px at 13 h. (C) Bars are the px/PX ratio ±
SEM of allele-specific expression measured by real-time PCR at the indicated
cell cycle phases, **P < 0.005, late S/G2 vs. S; ΔΔ P < 0.005, late S/G2 vs. G1.
(D) The px/PX ratio of allele-specific expression measured in eight human
biopsies of normal and neoplastic endometrium and in eight low- and high-
grade breast cancers heterozygous for the XbaI polymorphic site; bars are
average values ± SEM; # in this case px was the only allele transcribed, ***P <
0.001, **P < 0.01, *P < 0.05 px versus PX or Px ratio of transcription. (E)
ChIPs with anti-total Pol II and anti-phosphorylated isoforms of Ser2 and
Ser5 of the CTD; real-time PCRs were done using primers upstream (5′)
downstream (3′) or within (At) the attenuation site; bars are average values ±
SEM of the fold enrichment relative to the total Pol II, ***P < 0.001
comparing 3′ and At versus 5′ amplifications. (F) The same ChIP samples
reported in E, but amplifications were carried out with allele-specific real-
time PCR; ***P < 0.001 and **P < 0.01 comparing the px/PX ratio from ChIP
anti-Pol II Ser2 or Ser5 versus ChIP input, respectively. Data were collected
from at least two independent experiments performed in triplicate. P values
were calculated with one way ANOVA followed by Bonferroni’s post test.
Fig. 6. The effects of c-MYB overexpression on the block of Pol II elonga-
tion in MCF7 cells. (A) ChIP analysis of the ERα intron 1 site and CYCB2
promoter (as positive control) using anti-HA and anti-cMYB antibodies and
mouse IgG. (B) Pausing ratio calculated as in Fig. 2D; bars represent mean
values ± SEM, *P < 0.05 MCF-7::HA-cMYB versus MCF-7::empty vector. (C)
ERα mRNA levels measured by real-time PCR; bars represent means ± SEM,
**P < 0.001 MCF-7 HA-cMYB versus MCF-7 empty vector. (D) ChIPs per-
formed with anti-HA antibody followed by allele-specific real-time PCR; bars
represent the ratio of px/PX template, *P < 0.01 MCF-7::HA-cMYB versus
MCF-7::empty vector. (E) Ratio of px/PX mRNA measured by allele-specific
real-time PCR; bars represent mean values ± SEM, **P < 0.01 MCF-7::HA-
cMYB versus MCF-7::empty vector. Data were collected in at least two in-
dependent experiments performed in triplicate. P values were calculated
with one way ANOVA followed by Bonferroni’s post test.
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ectopical increase of c-MYB expression during S-phase by tran-
sient transfection in thymidine synchronized cells, produced a
correspondent increased level of ERα expression selectively in
c-MYB transfected samples (SI Appendix, Fig. S8), again in-
dicating that c-MYB plays a critical role for the release of the Pol
II blockage at the intron 1 polymorphic site during the cell cycle.
The reciprocal regulation between c-MYB and ERα in humans is
also well supported by the significant correlation of their expres-
sion found in clinical samples showed by previous studies (21–23)
and in our own analysis of public databases (SI Appendix, Fig. S9).
We propose that the coordinate regulation of these two tran-
scription factors controlling their oscillatory expression during cell
cycle represents a novel concept to better understand the hor-
mone action throughout the body.
Discussion
Our study provides the explanation for the genetic association
between the PvuII/XbaI polymorphisms and several aspects of
estrogen physio-pathology including neoplastic transformation of
tissues target of estrogen signaling, thus suggesting that the ERα
oscillatory expression is involved in these processes. Our finding
that the magnitude of pausing at the intron 1 site increases
during progression toward a hormone-refractory ERα-negative
breast cancer, underlies the clinical relevance of this molecular
switch. The ERα oscillatory expression is tightly controlled by an
evolutionary conserved site (SI Appendix, Fig. S5A) where both
SNPs map; the mechanism controlling fluctuation involves the
c-MYB proto-oncogene, which modulates the Pol II release from
the blockage by recognizing, with different affinities, the four
haplotypes at the PvuII and XbaI sites (Fig. 7).
Decrypting PvuII and XbaI Polymorphic Sites in the ERα Intron 1 Links
Pol II Elongation to Estrogen-Dependent Carcinogenesis. The present
study shows that the association among PvuII and XbaI poly-
morphisms and hormonal tumorigenesis is likely due to the
perturbation of the oscillatory expression of ERα occurring
during cell division. Oscillatory expression of the receptor is
required for a correct cell division: disruption of the mechanism
by ERα constitutive expression was shown to arrest the cell cycle
(24) and to induce apoptosis (25) also in the absence of ligand,
indicating that hormone-independent pathways are playing a
role in the regulation of cell division (26). According to our data,
c-MYB, during cell cycle, induces a higher Pol II elongation in
the presence of the px haplotype, thus increasing the amplitude
and length of the receptor oscillatory expression in proliferating
cells; we may speculate that this is causing the activation of over-
lapping, but not coincident genetic programs during cell cycle, with
a differential ability of the receptor to couple its expression with
other rhythmic transcriptional programs whose disruption may
contribute to the development of hormone-dependent neoplasia
(27). It is tempting to speculate that ERα oscillatory expression is
part of a cell cycle oscillator (28, 29) involving c-MYB in a positive
feed-back loop (21); in agreement with our study, an increasing
number of clinical (22, 23) and molecular data (21, 30) suggest
a direct involvement of c-MYB in mammary carcinogenesis. Fu-
ture studies should clarify the relation, if any, of the receptor os-
cillation in the tumor initiating cell and the tumor suppressive
functions of circadian oscillators (27); in line with this idea, oscil-
lation of bHLH transcription factors was recently demonstrated to
control multipotency and fate in mouse progenitors (31).
Clinical Implications. Selected studies have tested the predictive
value of using the PvuII and XbaI polymorphisms as markers of
responsiveness to hormone therapy (32, 33), however, a firm
evidence that these polymorphisms can be used as genetic
markers to identify responders to hormonal therapy or patients
likely to develop hormonal resistance is still lacking. A major
limitation of the past studies was the fact that they did not take
into consideration the haplotype conformation of both SNPs in
each patient, whereas we demonstrated this is likely to be most
relevant compared with each single polymorphism. The present
study may have a significant impact in the generation of novel
clinically useful markers. Our results provide the molecular basis
for the changes in the receptor status that patients may experi-
ence during tumor progression in metastatic disease, changes
that significantly influence patient survival (15). The possibility
to develop the analysis of nuclear transcripts into clinically useful
biomarkers for metastatic patients has to be carefully evaluated
through a systematic study involving a sufficiently large number
of patients and the normalization of a number of expected con-
founders, including tumor stage, haplotype, number of proliferating
cells and level of c-MYB in the neoplastic tissue. Notwithstanding
these confounders, the preliminary inspection made by sorting the
patient samples with a decreasing pausing ratio (SI Appendix, Table
S1), allowed to observe an inverse correlation of the TLI (thymi-
dine labeling index) and pausing in 10 of 13 samples where this
index was available (SI Appendix, Table S5). This preliminary evi-
dence is certainly encouraging a more in depth investigation of the
primary transcripts and pausing in a wider collection of breast
cancer cases aimed at establishing their relation with the pro-
liferation of cancer cells as well as their ability to predict a hormone
refractory phenotype. Our data also provide a possible explanation
of decades of immunohistochemistry observations showing that
ERα positive cells in breast tumor specimen are quite variable
(1–100%) and that clinical responses to hormonal therapies can be
demonstrated in patients with tumors presenting as few as 1–10% of
weakly ERα-positive cells. Multiple explanations were proposed to
account for the variability of ERα expression observed in breast
cancers, including differences in the subclones originated by the
tumor originating cells (cancer stem cells) or the clonal selection
mechanism intervening during tumor formation (34). Our results
indicate that cellular heterogeneity, might be due, at least in part, to
the presence of different number of cells in the S-phase of the cell
cycle in the histological samples. In favor of this hypothesis, several
studies showed a substantial lack of colocalization between S-phase
markers and ERα expression in mouse (35), rat (36), bovine (37),
and human tissues (38). Because immunohistochemistry analysis
offers a snapshot image of the tumor cells, we may conclude that
the technique is likely underestimating the number of ERα positive
cells limiting the counts to those cells that are not in S-phase. Future
studies should re-evaluate ERα immunodetections as a tumor
marker in light of the results of the present study. Finally, it is ex-
pected that the identification of the key factors underlying the
mechanism of ERα instability during breast cancer progression may
provide also a new impulse in the development of therapeutics
aimed at sensitizing hormone refractory cancers.
Methods
Run-On Assay. Cells (50 × 106) were incubated for 5 min in a lysis buffer
(10 mM Tris·HCl, pH 7.4, 3 mM MgCl2, 0.5% Nonidet P-40, and 10 mM NaCl)
and nuclei were pelleted by microfuge centrifugation. Nuclear run-on
assays were performed as described (39). Four-h prehybridization and 24-h
Fig. 7. Model for the control of ERα oscillatory expression during cell cycle
by transcriptional pausing. The presence of px in the pausing sequence
allows a stronger binding of c-MYB and facilitates the transcription of
elongating Pol II (CTD phosphorylated in Ser2 and Ser5) compared with the
PX allele, therefore producing an increased amplitude of receptor oscillatory
expression during cell cycle.
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hybridization were carried on in Church and Gilbert’s solution at 72 °C; 2 ×
106 cpm/mL were used in the hybridization reaction. After two washes of 45
min at 72 °C in a solution containing 40 mM NaHP0, 1% SDS, and 1 mM
EDTA, filters were exposed to autoradiographic films. Details concerning the
run on probes can be found in SI Appendix, Methods.
Real-Time PCR for Amplification and Quantitation of the Primary ERα Transcripts.
Templates were amplified using the TAQMAN Universal PCR amplification kit
(Applied Biosystems) in a thermocycler (ABI Prism 7000, Applied Biosystems).
The level of intron 1 amplicons reported in Fig. 2 B and C were normalized
on the constitutively expressed gene 36B4 and on primer/probe efficiency
using the 2-ΔΔCt method. Absolute quantification of the primary transcripts
shown in Figs. 2 D and E and 6B and SI Appendix, Fig. S2 was carried out using
the standard curve procedure according to the manufacturer guidelines
(Applied Biosystems). Both 5′-SNP and end amplicons showed a linear trend
down to 10–100 copy of template (SI Appendix, Fig. S2). Primers, probes and
the plasmid used in the assay are detailed in the SI Appendix, Methods.
Allele-Specific Transcription. The protocol for monitoring allele-specific tran-
scriptionwasdeveloped fromapreset SNPgenotypingassay (AppliedBiosystems).
Template cDNAswere obtained by randomprimer retro-transcription of 0.1 μgof
total RNA. The ratio of allele-specific cDNAs was determined by using the 2-ΔΔCt
method and standardized on efficiency of the two TAQMAN probes used to
detect each allele.
Chromatin Immunoprecipitation. ChIPwere carried out as described.MCF-7 cells
were incubated in 1% of formaldehyde for 10 min at 22 °C, and the reaction
was stopped with 0.125 M glycine. Sonicated chromatin was incubated with
4 μg of anti-HA (Roche 1583816), anti-MYB (Millipore 05–175), anti-total Pol II
(Santa Cruz Biotechnology), anti-phosphorylated isoforms of Ser5 and Ser2 of
the CTD (Abcam), and 4 μg of mouse IgG (Upstate 12–371) as negative control.
For PCR analysis, 1 μL of template in 30 μL of total reaction were used. PCR was
performed with HOT-MASTER Taq (Eppendorf). Primers used for real-time PCR
amplifications are listed in SI Appendix, Methods.
Human Tumors. All human tumor specimens were obtained in accordance
with the Independent Ethics Committee (CEI) of the “Fondazione IRCCS
Istituto Nazionale dei Tumori,” Milan, Italy and the main tumor features are
listed in SI Appendix, Tables S1–S3.
Genotyping. Genomic DNA from cell lines, human endometrial and breast
tissues were genotyped with the SNPs genotyping assay (Applied Biosystems)
and haplotypes were determined by restriction enzyme analysis of PCR-
amplified DNA fragments from genomic DNAs.
Statistical Analysis. Statistical significance of differences between means was
determined applying Student t test or ANOVA followed by Bonferroni’s test.
Additional methods can be found in SI Appendix, Methods.
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Fig. S1. Pol II attenuation in T47D and SKER3 cell lines. Nuclei generation and in vitro transcription assay were carried out as reported in material 
and methods. (A) Schematic representation of the human ERα locus (1) with the genomic position of the run on probes. (B) Run on assay on T47D 
breast cancer cell line; a similar arrest of Pol II elongation at intron 1 found in MCF-7 cells (Fig. 1) is also present in  the T47D breast cancer cell 
line. (C) Run on from SK-ER3 a stably transfected neuroblastoma cell line constitutively expressing ERα cDNA (2). 
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Fig. S2. Absolute quantification of the pausing mechanism by quantitative RT-PCR. (A) The standard curve was generated by real time PCR 
amplification using as template increasing dilutions of a plasmid containing the 532 bp region spanning the two amplicons (5’SNP and end); the 
real time PCR showed a linear amplification down to 10 (5’-SNP amplicon) or 100 (end amplicon)  molecules of template. (B) The standard curve 
was used to measure the absolute number of template molecules amplified by the two amplicons in 0.1 μg of retrotranscribed total RNA obtained 
from  MCF-7, T47D and ZR 75.1 breast cancer cell lines. The same procedure was applied to estimate the number of  nuclear RNA transcripts 
obtained from breast tumors (see Fig. 2, Supplementary SI Appendix Table S1 and Table S2). 
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Fig. S3. Supplementary results supporting the oscillatory expression of ERα during cell cycle. (A) Immunocytochemistry of non-synchronized 
MCF-7 cells carried out with the H222 anti-ERα antibody; white and black arrows indicate clonal cells not expressing or expressing ERα, 
respectively. B) Western blot analysis of ERα expression in protein extracts from MCF-7 cells treated with vehicle (c) or different synchronizing 
agents (3) including 2 mM thymidine (Th), 10 nM interleukin-1 α (Il), 4 nM staurosporine (St), 20 μM simvastatin (Sv) and 1 mM hydroxyurea 
(Hy), 1.7 nM nocodazole (No). C)  Dynamic of ERα fluctuation in MCF-7 cells synchronized with a nocodazole treatment. Briefly, cells were 
treated with 1.7 nM nocodazole; mitotic cells loosely attached to the Petri’s dish were recovered by gentle pipetting; the drug was washed away 
before seeding the recovered cells in fresh medium and the cells were then collected at different phase of the cell cycle for Western blot analysis. 
Filters were immunostained with the antibody directed against ERα (H222);  anti-tubulin or ponceau staining are shown as a relative measure of the 
proteins loaded in the gels.   
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Fig. S4. Oscillatory expression of ER in ZR 75.1 breast cancer cell line. Similarly to what observed in MCF-7 cells, ER mRNA (A) and protein 
(B) is low during the S phase and increase at the end of S/beginning of the G2 phase, reaching the peak of  expression in G1. C) Cell cycle phases 
were determined by cytofluorimetry.
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Fig. S5. Evolutionary conservation and functional significance of the 76 bp DNA sequence of ERα intron 1 containing  the PvuII and XbaI 
polymorphic sites. (A) The 76 bp intron 1 sequence of ERα spanning the polymorphic sites is highly conserved in mammalian. Boxes indicate the 
PuvII (IVS-397T/C) and XbaI (IVS-351A/G) restriction sites, arrows indicate the RFLPs which are also highlighted in bold; single nucleotide 
differences among species are reported in grey, while conserved nucleotide are highlighted with asterisks on the bottom part of the alignment. 
Alignments were performed with CLUSTAL 2.0.11 Multiple Sequence Alignments software. (B) Scheme of the pGL3 vector carrying the 76inter1 
DNA fragment in sense (+) or antisense (-) orientations. Bars are average values ± SEM of the relative light units (RLU) normalized on β-
galactosidase activity, ** P<0.01 cells transfected with the 76inter1 sequence versus the empty vector. 
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Fig. S6. Supplementary results of the c-Myb effects on the control of ERα expression. (A) Western blot analysis of transiently transfected MCF-7 
cells with pHA-MYB (4) or with the empty vector of the experiments reported in Fig. 6. (B) Control of the ChIP experiment of Fig. 6; the 
immunoprecipitated chromatin was PCR amplified with an amplicon mapping 35 Kb upstream the pausing site. (C) Luciferase activity measured in 
MCF-7 24h after transfection with the reporter constructs carrying the four different haplotypes (see also Fig. 5A and B). Bars represent mean 
values ± SEM,  ***P<0.001 and * P<0.05 MCF-7::HA-cMYB versus MCF-7::empty vector. (D) A cluster of high confident (>96%) c-MYB  
binding sites (M1, M2, M3) were mapped using the algorithm of Farré and colleagues (5); the “M3” site was previously characterized (6). (E) 
western blot (E) and real time PCR  (F) analysis of c-MYB expression and pausing ration in MCF-7 infected with a shMYB expressing vector 
kindly provided by Prof. T. Gonda (University of Queensland, Australia) (7); pausing ratio was set to 1 for the cells infected with the control 
scramble vector (SCR).  
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Fig. S7 c-MYB levels are low during the S-phase and peaks in G1-phase of the cell cycle in breast cancer cell lines. Real time PCR analysis of c-
MYB mRNA was carried out on the samples of Fig. 3 and SI Appendix Fig. S4. In thymidine synchronized MCF-7 (A) as well as in ZR 75.1 (B) 
cell lines the c-MYB level of expression is low during the S-phase reaching the highest level during the G1-phase of the cell cycle.  
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Fig. S8 Ectopical expression of c-MYB increases ERα expression during the S-phase of the cell cycle. A) Semiquantitative real time PCR analysis 
to measure c-MYB mRNA levels during the S-phase of the cell cycle in thymidine synchronized MCF-7 cells transfected with pCDNA3HA-MYB 
(black bar) or with the empty vector (white bar).  *** P <0.001 MYB versus empty vector transfected cells: P value was calculated with one way 
ANOVA followed by Bonferroni’s post test. B) Western blot analysis of the ER levels in protein extracts from the same cells as in (A). C)  
Immunocytochemistry experiments aimed at assessing whether c-MYB overexpression  induces endogenous ERα expression during the S-phase of 
the cell cycle. To this purpose MCF-7 cells were transfected with an EGFP overexpressing vector (pEGFP-N1) together with a c-MYB 
overexpressing vector (PCDNA3-HA-MYB) or the empty vector (PCDNA3) as control; the plasmid ratio in the transfection was 1 (pEGFP-N1) : 
10 (pCDNA3HA-MYB or pCDNA3), thus each EGFP expressing cell had a high likelihood to be transfected also with the c-MYB (or empty 
vector) expression vector. Transfected cells were thymidine synchronized and analyzed  by immunocytochemistry in the S-phase of the cell cycle. 
Immunocytochemistry was carried out with an anti-EGFP (green) and anti-ERα (red) antibodies; co-localization (yellow staining) were mainly 
present in c-MYB overexpressing cells. D) Graph values  represent the ratio between yellow cells (green positive + red positive) versus green cells 
obtained from immunocytochemistry  experiment indicated in (C); bars in the graph are average values of the cell counts obtained from n. 3  fields 
(20X); ** P <0.01 yellow versus green cells. P values were calculated with one way ANOVA followed by multiple Bonferroni’s test. 
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Fig. S9 Correlation between ER and c-MYB expression in breast cancer patients. The “205225_at” probe set was considered as reporters for ER 
gene expression, while “204798_at” was used for c-MYB  (number of patients = 684).  
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Table S1 –  low and high grade breast cancers  
 
 
ID  Grade ERα PgR histotype haplotype 
5’-SNP n. of 
transcripts (1) 
end  n. of 
transcripts (2) 
Pausing 
rate 
px vs PX  TLI (3) 
1 Low Positive negative IDC PX/px 610265 61407 9.94 340 0.1 
2 Low Positive positive IDC  PX/Px 20328 1359 14.96 794 0.3 
3 Low Positive positive IDC+ LCIS + ILC  px/px 49359 57502 0.86 n.d. 4.6 
4 Low Positive positive IDC PX/Px 49359 15008 3.29 0.6 n.a 
5 Low Positive positive IDC + ILC px/px 5275 2546 2.07 n.d. 0.2 
6 Low Positive positive IDC PX/PX 2787 8808 0.32 n.d. 6.6 
7 Low Positive positive IDC PX/px 55503 88458 0.63 2897 4.2 
8 Low Positive positive IDC + ILC PX/px 11816 1245 9.49 5 0.8 
9 Low Positive positive IDC+DCIS px/px 51579 36304 1.42 n.d. 7.3 
10 Low Positive positive IDC px/px  895 166 5.39 n.d. 4.3 
11 Low Positive positive IDC PX/px 55503 100146 0.55 n.d. 2.3 
12 High positive positive IDC Px/px 6525 30 216.88 n.d. 3.6 
13 High positive positive IDC PX/px 10130 10649 0.95 4.0 n.a 
14 High positive positive IDC px/px 2534 699 3.62 n.d. n.a 
15 High positive positive IDC PX/PX 970 18 55.33 n.d. n.a 
16 High positive negative IDC PX/Px 19170 3193 6.00 506 n.a 
17 High positive negative IDC PX/px 3793 426 8.91 0.7 n.a 
18 High positive positive IDC px/px 19030 5208 3.65 n.d. n.a 
19 High positive positive IDC px/px 25515 1561 16.34 n.d. n.a 
20 High positive negative IDC PX/PX 76633 17368 4.41 n.d. 1.7 
21 High positive positive IDC+DCIS PX/PX 204685 75886 2.70 n.d. 3.5 
22 High positive negative IDC + DCIS px/px 472145 5521 85.52 n.d. n.a 
(1) and (2):  absolute number of template molecules  in 0.1 µg total RNA  measured with the standard curve procedure; amplicons were mapping 
(1) before (5’-SNP amplicon),  and (2) after (end amplicon)  the two intronic SNPs (see map of Fig. 2A). (3) TLI = Thymidine Labeling Index, % 
of cells incorporating 
3
H-thymidine (n. 2000 analysed in total). The results reported in Fig. 2D refer to all the specimens of SI Appendix Table S1. 
n.d.: not detectable. n.a.: not available   
 Table S2 – primary breast cancers and corresponding relapses 
 
 
 
Patient Type ER PgR 
5’-SNP n. of 
transcripts (1) 
end n. of 
transcripts (2) 
Pausing rate 
1 Primary Positive positive 27255 6435 4.2 
1 Relapse negative positive 6289 152 41.3 
  2 Primary positive positive 260151 40504 6.4 
  2 Relapse negative negative 15612 177 88.0 
  3 Primary positive negative 55502 117593 0.4 
 3 Relapse negative positive 2188 373 5.9 
 4 Primary positive positive 204685 42318 4.8 
 4 Relapse negative positive 2849 n.d. >100 
 5 Primary positive positive 81860 13451 6.1 
 5 Relapse negative positive 60607 929 65.2 
 6 Primary positive positive 1573 475 3.3 
 6 Relapse negative positive 54,4 n.d. >50 
 7 Primary positive positive 58425 52679 1.1 
 7 Relapse negative positive 203 n.d. >100 
 8 Primary positive positive 2844 2865 1.0 
 8 Relapse positive negative 92223 20707 4.5 
 9 Primary positive positive 11207 8680 1.3 
 9 Relapse positive negative 2961 444 6.7 
 (1) and (2):  absolute number of template molecules in 0.1 µg of total RNA measured with the standard 
curve procedure; amplicons were mapping  (1) before (5’-SNP amplicon)  and (2) after (end amplicon) 
the two intronic SNPs (see map of Fig. 2A). The results reported in Fig. 2E refer to all the specimens of 
SI Appendix Table S2. n.d.= not detectable 
 
 
 
 
 Table S3 - normal and neoplastic endometrium 
 
 
 
 
 
Patient Type px vs PX  genotype 
1 normal endometrium 0.93 PX/px 
2 normal endometrium 1.02 PX/px 
3 normal endometrium 4.35 PX/px 
4 normal endometrium 1.69 PX/Px 
5 normal endometrium 1.43 PX/px 
6 endometrial tumor >1000 (1) PX/px 
7 endometrial tumor 7.14 PX/px 
8 endometrial tumor 74.1 PX/px 
 (1) the PX allele was undetectable and the  number of the PX template molecules was lower than 1000 
times as compared to the px template; thus the ratio could not be calculated because of the limit of the 
detection system. The results shown in Fig. 2C were obtained from the biopsies of patient 5 and patient 6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table S4 – factors tested for their ability to increase or decrease Pol II elongation through the px site in transient transfection experiments 
 
Stimulus 
px fold 
increase* 
P value 
Dexametasone  (10
-7 
M) 1.2 0.63 
Progesterone  (10
-7
 M) 1.1 0.91 
Retinoic acid  (10
-7 
M) 0.6 0.09 
Genistein  (25 uM) 0.7 0.28 
ERalpha 1.5 0.11 
P53 1.1 0.83 
c-MYB 1.9 <0.0001 
c-MYC 1.1 0.32 
NFYA 0.71 0.009 
CBP 1.3 0.92 
SRC1 1.5 0.08 
SRC3 1.2 0.06 
CDK9/CyclinT1 1.2 0.25 
FUS (siRNA) 0.7 0.15 
PTMA 1.1 0.15 
H89 1.2 0.29 
Trichostatin A 0.85 0.09 
Phorbol ester (PMA) 0,24 0.0006 
Tyrphostin 1.5 0.18 
Staurosporine 1.3 0.39 
LeptomycinB 0.30 0.004 
Adenine 100uM 0.6 0.24 
ATP 100uM 0.7 0.22 
Lysine 100uM 0.80 0.62 
LiCl 0.46 0.005 
LY294002 1.11 0.93 
* Expressed as RLU/LacZ of the vector carrying the 78bp  fragment versus  
RLU/LacZ  of the empty vector (the assay is shown in SI Appendix Fig. S5B) 
 
Table S5 - association between proliferation marker TLI (Thymidine Labeling Index) and pausing 
 
 
 
 
 
 
 
 
 
 
Patient 
5’-SNP n. of 
transcripts 
end  n. of 
transcripts 
pausing 
ratio 
TLI 
2 20328 1359 15.0 0.3 
1 610265 61407 9.9 0.1 
8 11816 1245 9.5 0.8 
21 204685 75886 2.7 1.7 
5 5275 2546 2.1 0.2 
9 51579 36304 1.4 7.3 
3 49359 57502 0.9 4.6 
7 55503 88458 0.6 4.2 
11 55503 100146 0.6 2.3 
6 2787 8808 0.3 6.6 
Data are taken from SI Appendix Table S2; patients are ordered by decreasing 
pausing ratio. Inverse correlation between pausing ratio and TLI was 
observed for all patients, but three exception (patients 10, 12, 22) that were 
omitted from the list. 
 
 
 
 
  
Supporting Methods 
 
Primers, probes and plasmid used in real-time PCR for amplification and quantitation of the primary ERα transcripts. The following 
primers and probes specific for ERα intron 1 and the 36B4 coding sequence were used: start amplicon: forward 5’-
GCGCTGCGTTCAGAGTCAA-3’, reverse 5’-GGTAAGTGGGTGGAGAGTACGTTT-3’, probe 5’-TTCTCTCGCCGGGCAGCTGAA-3’; 5’-
SNP amplicon: forward 5’-GGCTCAAACTACAGGGCTTAAACA-3’, reverse 5’-TGGAATCCCAGCACTTTGG-3’, probe 5’-
TCTCCTGCTTTGGCC-3’; end amplicon: 5’-forward 5’-AATAAACAATTTCCCCTCAAGGTTAA-3’, reverse 5’-
CCTCTTGCCGTCTGTTGCA-3’, probe 5’-TAATAGGCAACACCTTTTG-3’ 36B4 amplicon: forward 5’-GGCGACCTGGAAGTCCAACT-3’, 
reverse 5’-CCATCAGCACCACAGCCTTC-3’, probe 5’-ATCTGCTGCATCTGCTTGGAGCCCA-3’. Primers were designed with Primer express 
2.0 software (Applied Biosystems) and preset to an annealing temperature of 60°C. The thermal profile of the 40 amplification cycles for each 
amplification reaction was: denaturation step at
 
95° C for 15 s and an annealing/extension step at 60° C
 
for 60 s. The primer/probe efficiency were 
determined in amplification experiments on genomic DNAs (obtained from MCF-7 and from endometrial samples) setting the end amplicon to 1: 
these values were found to be constant in all reactions and used as normalizing factors. All amplicons
  
generated a single amplification band, thus 
reflecting the specificity of
 
the primers.  
The standard curve was generated by real time PCR amplification using as template serial plasmid dilutions (from 1 million to one copy) of a 
plasmid containing the 532 bp region spanning the two amplicons (5’SNP and end). The threshold Ct was plotted with the logarithm of the copy 
number and the resulting curve showed a linear trend down to 10 (5’-SNP amplicon) or 100 (end amplicon) molecules of template.  
 ChIP primers. Primers used for real time PCR amplifications of Fig. 5F are: (5’)-amplicon (upstream the attenuation site)  forward 5’- 
GCCAAGTCCTGGGCCAATAT-3’, reverse 5’- TCTCGCCAGACCAGACATAGG-3’; (At)-amplicon (on the attenuation site) forward 5’- 
AGGGTTATGTGGCAATGACG-3’, reverse 5’- CCTGCACCAGAATATGTTACCT-3’; (3’)-amplicon (downstream the attenuation site) forward 
5’- CTGACAGCAGCTTAGGCTAACCA -3’, reverse 5’-GCCCCACACTTAAGATTAAAAAATGA -3’. The primer sequences of the human 
ER intron 1 used in Fig. 6A, Fig. 6E and SI Appendix Fig. S5B were  hESR1-Forward 5’-AGGGTTATGTGGCAATGACG-3’ hESR1-Reverse 
5’- CCTGCACCAGAATATGTTACCT-3’ (close to the SNPs) and hESR1-Forward 5’-CAGAGTCAAGTTCTCTCGCC-3’ hESR1-Reverse 5’-
GAGACCTTCCCAAGTGACTC-3’ (-35 Kb from the SNPs); for the CYCB2 promoter the PCR conditions were previously reported (9). 
 
Plasmids. All ERα fragments used in the run-on analysis were subcloned into a pBluescript II KS vector (Stratagene). Exons 1, 2, 4 fragments were 
obtained by PCR amplification from the cDNA vector pSWMTERα (kindly provided by G. Greene) using the following primers: exon 1, forward 
5’-ATGACCCTCCAC-3’, reverse 5’-GTAGTAGGGCACCTGCTGG-3’; exon 2, forward 5’-GCCAAATTCAG-3’, reverse 5’-
AGATTCCATAGCCATAGTT, exon 4, forward GACCAGAGAGGAA-3’, reverse 5’-TCTTCGCCCAGTTG-3’. The exon 8 fragment 
Bsrg1/Cla1 from pSWMTERα was subcloned into pBluescript II KS, while the intron 1 Pst1/BssHII fragment was subcloned from the λGHER1 
(kindly provided by P. Chambon, IGBMC/CNRS UMR7104/Inserm U964/Collège de France, Université de Strasbourg, Illkirch-Cedex, Strasbourg, 
F). Single strand probes were generated according to the manufacturer’s instruction using a helper phage M13K07 (New England Biolabs). For the 
functional study, the 76inter1 fragment containing the two RFLPs in the four different haplotype configurations were chemically synthesized 
(Primm); NcoI sites were introduced in the DNA termini to allow subcloning into the Nco1 site of the pGL3 control vector (Promega). The plasmid 
used for the absolute quantification of the real time PCR templates with the standard curve procedure was obtained by cloning the PCR genomic 
fragment of 532 bp (generated with the more external primers used in real time PCR for the 5’-SNP and end amplicons) into pCR 2.1 vector 
(Invitrogen). pHA-Myb expression vector was kindly gift by Giuseppe Raschellà (4). 
 
Northern blot, western blot. Northern and western blots were performed as previously described (8). For northern blot 20 μg total RNA was used 
in the assay. The entire ERα cDNA was labeled with 32P and used as a probe; membranes were exposed to autoradiography film for 2 days.  
Western blots were carried out on 20 μg  total proteins; immunodetection of the western blot was done with the anti-ERα antibody H222 (1:2000) 
and an anti-rat IgG conjugated with horseradish peroxidase as the secondary antibody (1: 5000); detection was performed using an enhanced 
chemiluminescence (ECL) system (Amersham).  The primary antibody was monoclonal H222 (kindly provided by G. Greene, University of 
Chicago). Detection was performed using an ABC kit (Vector Laboratories).  
 
Thymidine synchronization and cytofluorimetry.  
For the synchronization experiments, cells were treated at least for a length of time necessary for duplication with 200 µM thymidine. The block 
was released by washing the cells twice with PBS and re-supplementing the culture with fresh pre-warmed medium. Synchronously cycling cells 
were then collected at different time points for cytofluorimetry, run on, northern blot and western blot analysis.  
For the cytofluorimetry experiments, cells were trypsinized and suspended in cold PBS; aggregates were dissolved by gentle pipetting before drop-
by-drop instillation of cold ethanol (final concentration 62%). Before detection with a cytofluorimeter (Beckton Dickinson, FACS Calubur), cells 
were pelleted and resuspended in a staining solution (10 μg/ml RNAseA, 1% NP40, 5 μg/ml propidium iodide).   
 
Immunocytochemistry. H222 anti-ER antibody was diluted 1:2000 in phosphate-buffered saline (PBS) with 10% rabbit serum and 0.3% Tween 
20, while the secondary antibody was a biotinylated anti rat IgG (Vector Laboratories) diluted 1:2000 in PBS with 1% goat serum and 0.1% Tween 
20. Antibody/antigen detection was performed using an ABC kit (Vector Laboratories) according to the manufacturer’s instructions. 
Immunostaining was visualized by exposure to 3,3’-diaminobenzidine. 
 
Cell culture and transfection. MCF-7, T47D and ZR 75.1 cell lines were routinely grown at 37° C in RPMI 1640 (Sigma) supplemented with 10 
% FBS. Transfections and reporter assays were carried out with the calcium phosphate precipitate procedures as described earlier (8). Transfections 
of c-MYB were carried out with LIPOFECTAMINE LTX (Invitrogen). Briefly, 1.8x10
5
 MCF7cells were plated in triplicate in 24-mm plate and 
transfected with following the manufacturer's instructions. Five hours later, the liposome complexes were removed and cells were grown in DMEM 
plus 1% FBS medium for 24 h.  
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